Cargando…
Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) presents as an unmet clinical challenge for drug delivery due to its unique hypoxic biology. Vinblastine-N-Oxide (CPD100) is a hypoxia-activated prodrug (HAP) that selectively converts to its parent compound, vinblastine, a potent cytotoxic agent, under oxygen...
Autores principales: | Shah, Vidhi M., Dorrell, Craig, Al-Fatease, Adel, Allen-Petersen, Brittany L., Woo, Yeonhee, Bortnyak, Yuliya, Gheewala, Rohi, Sheppard, Brett C., Sears, Rosalie C., Alani, Adam WG. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031349/ https://www.ncbi.nlm.nih.gov/pubmed/35456547 http://dx.doi.org/10.3390/pharmaceutics14040713 |
Ejemplares similares
-
Computational Prodrug Design Methodology for Liposome
Formulability Enhancement of Small-Molecule APIs
por: Balouch, Martin, et al.
Publicado: (2023) -
Recent Advances in Long-Acting Drug Delivery and Formulations
por: Al Fatease, Adel, et al.
Publicado: (2023) -
An esterase-activatable prodrug formulated liposome strategy: potentiating the anticancer therapeutic efficacy and drug safety
por: Shi, Linlin, et al.
Publicado: (2021) -
Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma
por: Alekseeva, Anna A, et al.
Publicado: (2017) -
Dexamethasone Loaded Liposomes by Thin-Film Hydration and Microfluidic Procedures: Formulation Challenges
por: Al-Amin, MD, et al.
Publicado: (2020)